Jan-Olav Henck, PhD,
chief scientific officer
Jan-Olav Henck, PhD, chief scientific officer at Aptuit, discusses strategies and considerations in polymorph screening with Patricia Van Arnum, senior editor of Pharmaceutical Technology (Posted November 2011).
Ash Stevens has received FDA’s approval to manufacture Takeda’s multiple myeloma drug, ixazomib, at its facility in Riverview, Michigan.
Operations at Catalent’s Beinheim, France, softgel facility were suspended following suspected deliberate action to misplace capsules.
CDMO Xcelience opens new facility in Tampa, FL, for formulation and analytical services.
Finalizing GMP requirements and quality standards for the development,
manufacture, and clinical testing of ATMPs in the EU is proving to be a complex task.
Robert Califf addresses questions about drug pricing at the Senate hearing to weigh his appointment to be the next commissioner of FDA.
The new executive director of the European Medicines Agency begins appointment.
Ingredients Insider Cynthia ChallenerAdvances in Heretocyclic Chemistry for API Synthesis